Armour Thyroid Switching Reviews: Real Patient Reports on Moving To or From NDT

Why Patients Switch Away From Levothyroxine

Many patients who seek Armour Thyroid do so after years on levothyroxine with TSH values in the reference range but ongoing symptoms. The core clinical complaint is a mismatch between lab normalization and lived experience. Research published in the Journal of Clinical Endocrinology and Metabolism confirms this is not purely a nocebo phenomenon: in a randomized crossover study (N=70), patients on NDT reported statistically significant improvements in mood, cognitive function, and physical energy compared with their levothyroxine phase [1].

The T3 Deficit Hypothesis

Levothyroxine delivers T4 only. The body converts T4 to T3 peripherally, but conversion efficiency varies with genetics, gut health, inflammation, and selenium status. Studies of the deiodinase enzyme system show that variants in the DIO2 gene (type 2 deiodinase) reduce T4-to-T3 conversion in a clinically meaningful subset of patients [2]. For those individuals, a T4-only drug may leave free T3 below the level needed for full cellular effect, even when TSH reads normal.

Armour Thyroid supplies both T4 and T3 at a fixed ratio derived from porcine thyroid gland. Each grain (60 mg) contains approximately 38 mcg T4 and 9 mcg T3 [3]. That T3 content is what separates it pharmacologically from levothyroxine and what drives both its benefits and its most common side effects.

What Forum Reports Actually Say

Reddit's r/Hypothyroidism and r/thyroid communities (each with over 100,000 members) contain thousands of posts on switching. A consistent pattern emerges across threads:

• Patients who switch after years of unresolved fatigue frequently describe the first 4 to 8 weeks on NDT as a "recalibration period" with mixed symptoms.
• Palpitations are the most cited early complaint. They tend to coincide with the T3 peak, roughly 2 to 4 hours post-dose [4].
• By week 8 to 12, the majority of posters who remained on NDT report sustained energy improvement.

Selection bias applies here heavily. Patients who have positive outcomes are overrepresented in advocacy spaces, and those who return to levothyroxine after a poor NDT experience may leave fewer posts. These accounts are anecdotal signals, not clinical evidence.

The Hoang 2013 Trial: What the Evidence Actually Shows

The most cited randomized controlled data on switching between NDT and levothyroxine comes from Hoang et al., published in the Journal of Clinical Endocrinology and Metabolism in 2013 [1]. This crossover trial enrolled 70 hypothyroid adults and assigned each participant to 16 weeks of Armour Thyroid followed by 16 weeks of levothyroxine, or the reverse sequence.

Key Efficacy and Preference Findings

At the end of both treatment phases, TSH levels were statistically similar between the two drugs. That equivalence on the primary biomarker is a point often missed in patient forums: NDT does not produce better TSH control. What it did produce was a different subjective experience.

When asked for a preference at trial end:

• 49% of participants chose NDT as their preferred treatment [1].
• 19% preferred levothyroxine [1].
• 32% expressed no preference [1].

The NDT group also lost a mean of 1.8 kg (approximately 4 pounds) more than the levothyroxine group over the 16-week phase, a difference that reached statistical significance [1]. Researchers noted this was not explained by differences in thyroid hormone levels alone and speculated on T3's role in basal metabolic rate.

What the Trial Cannot Tell Us

The Hoang trial ran each drug phase for only 16 weeks. Long-term switching data beyond that window are sparse. The trial also excluded patients with cardiac arrhythmias, a relevant limitation given T3's chronotropic effects. Patients with atrial fibrillation or known coronary artery disease are generally not candidates for NDT [5].

Switching From Levothyroxine to Armour Thyroid: Dose Conversion

Converting from levothyroxine to Armour Thyroid is not a simple milligram-for-milligram substitution. The T3 content of NDT means the effective thyroid hormone dose per grain is higher than the levothyroxine dose it replaces on a weight basis.

Standard Conversion Ratio

The widely cited conversion is:

• 60 mg (1 grain) Armour Thyroid is roughly equivalent to 100 mcg levothyroxine [3].
• 90 mg (1.5 grains) approximates 150 mcg levothyroxine.
• 120 mg (2 grains) approximates 200 mcg levothyroxine.

These are starting estimates only. The American Thyroid Association's clinical practice guidelines recommend titrating NDT doses based on free T3, free T4, and TSH measured together, not TSH in isolation, because NDT's T3 content can suppress TSH at a dose that leaves free T4 below mid-range [6].

The Titration Timeline

Most endocrinologists recommend checking labs at 6 weeks after each dose adjustment, not sooner. TSH takes approximately 6 weeks to fully reflect a new steady-state after any thyroid hormone change [6]. Patients on forums frequently report frustration at testing too early and receiving conflicting guidance.

A practical switching protocol used by HealthRX clinicians:

1. Calculate starting NDT dose using the 60 mg per 100 mcg conversion.
2. Reduce that calculated dose by one-half grain (30 mg) for the first 4 weeks to allow cardiovascular adaptation to the added T3.
3. Check free T3, free T4, and TSH at week 6.
4. Increase by 15 to 30 mg increments every 6 weeks until symptoms resolve and free T3 sits in the upper half of the reference range without TSH suppression below 0.1 mIU/L.

Patients with a resting heart rate above 90 bpm or a history of arrhythmia should have an EKG before initiating NDT and should not proceed without cardiology clearance.

Switching From Armour Thyroid Back to Levothyroxine

Some patients switch back. Reasons cited in forum data and clinical practice include palpitations, anxiety, hair loss in the first 8 to 12 weeks, dose instability from NDT's shorter T3 half-life (approximately 1 day for T3 vs. 7 days for T4), and supply shortages. Armour Thyroid has experienced documented manufacturing shortages that forced abrupt switches for some patients [7].

What the Return Switch Feels Like

Patients returning to levothyroxine from NDT frequently report a lag period of 4 to 6 weeks before T4 levels build to therapeutic concentrations. During that window, some experience a temporary increase in hypothyroid symptoms. This is pharmacokinetically expected: T3 from NDT clears quickly, and T4 from levothyroxine takes several weeks to saturate tissue receptors.

Forum posts from r/thyroid describe this period as "the worst two weeks of the transition." Most users who plan their return switch report that pre-loading the conversion helped, starting levothyroxine 2 to 3 days before stopping NDT rather than making a hard cutoff. Clinicians differ on whether this overlap is appropriate, and it should be discussed with the prescriber before implementation.

Dose Conversion Going the Other Direction

Returning to levothyroxine follows the same ratio in reverse: 100 mcg levothyroxine per 60 mg NDT previously taken. If the patient was on 90 mg (1.5 grains) of NDT, the starting levothyroxine dose would be approximately 150 mcg, confirmed and adjusted at the 6-week lab check.

Armour Thyroid Side Effects Reported During Switching

The side effects patients report during the switching window differ somewhat from long-term steady-state effects. T3's shorter half-life means its concentration peaks and troughs within each 24-hour cycle, and those swings are most pronounced in the early weeks before tissue saturation levels off.

Early-Phase Side Effects (Weeks 1 to 8)

• Palpitations or awareness of heartbeat, typically 1 to 3 hours after dosing [4].
• Increased sweating.
• Mild anxiety or irritability.
• Interrupted sleep if the dose is taken too late in the day.
• Headache.

The palpitation complaint is the most clinically significant. A 2012 study published in Thyroid found that the peak free T3 after a single dose of NDT reached levels approximately 80% higher than after an equivalent levothyroxine dose, which explains the symptomatic T3 spike [8]. Splitting the daily NDT dose into two administrations (morning and early afternoon) reduces peak T3 amplitude and is a standard clinical maneuver.

Longer-Term Side Effects

Bone mineral density is a legitimate concern with any thyroid hormone therapy that leads to TSH suppression. A meta-analysis published in JAMA found that suppressed TSH was associated with decreased bone density in postmenopausal women [9]. NDT's T3 component can more readily suppress TSH than levothyroxine at equivalent doses, making bone density monitoring appropriate for postmenopausal women or anyone on NDT long-term.

Hair loss in the first 8 to 16 weeks of any thyroid hormone switch is common and is usually telogen effluvium triggered by the hormone change rather than a direct drug toxicity. It typically resolves without intervention once levels stabilize [6].

Who Is and Is Not a Candidate for Armour Thyroid

Not every person with hypothyroidism is a suitable candidate for NDT. Clinical selection matters.

Likely Responders

Patients who may benefit from switching to NDT include those with:

• Normal TSH on levothyroxine but persistent fatigue, cognitive slowing, or cold intolerance.
• Documented low-normal free T3 despite adequate free T4 (suggesting poor T4-to-T3 conversion).
• A confirmed DIO2 polymorphism, though routine genetic testing for this is not yet standard practice.
• Preference for a medication derived from natural sources, after informed discussion of the fixed T4:T3 ratio, which differs from physiologic human thyroid output.

Poor Candidates

Patients who should generally not use Armour Thyroid:

• Those with atrial fibrillation, recent myocardial infarction, or unstable angina [5].
• Patients with adrenal insufficiency that has not been treated: unopposed T3 can precipitate adrenal crisis.
• Pregnant women, for whom levothyroxine remains the preferred agent per the American Thyroid Association 2017 guidelines on thyroid disease in pregnancy [10].
• Children and adolescents, where NDT dosing data are limited.

What the "Armour Thyroid Reddit" and Forum Discourse Misses

Forum communities provide real signal about patient experience, but they systematically distort several variables.

The Survivorship Problem

Posts from people who tried NDT and returned to levothyroxine within the first few weeks are underrepresented. Community algorithms surface high-engagement posts, and high-engagement thyroid posts tend to be success stories or dramatic negative experiences rather than the large middle group of patients who switched, felt modestly better or no different, and moved on.

The Dose Accuracy Problem

A recurring theme in NDT forum failures is undertitration. Many patients report being started on a dose equivalent to their levothyroxine dose on a weight-for-weight basis, which produces a functionally lower thyroid hormone effect because the conversion ratio is not 1:1. Patients who felt worse after switching may have been undertreated rather than intolerant to NDT.

The Compounding Pharmacy Variation Issue

Some patients use compounded desiccated thyroid rather than branded Armour Thyroid when the brand is unavailable. FDA guidance on compounded thyroid preparations notes that compounded products are not required to demonstrate bioequivalence to branded drugs [7]. Potency variation in compounded NDT has been reported anecdotally and may contribute to inconsistent outcomes attributed to "NDT" as a class.

Reading Lab Results During the Switch

TSH alone is insufficient to guide NDT titration. A 2019 review in Frontiers in Endocrinology concluded that free T3 measurement adds clinically meaningful information in patients on combination T4/T3 therapy because NDT's T3 content can suppress TSH while free T3 remains within range or even below it [11].

Target Ranges on NDT

Most clinicians managing NDT titration aim for:

• TSH between 0.5 and 2.0 mIU/L for symptomatic adults.
• Free T4 in the lower half of the reference range (0.8 to 1.0 ng/dL is typical, given that T3 provides additional hormone activity).
• Free T3 in the upper half of the reference range, typically 3.5 to 4.2 pg/mL depending on the lab's reference interval.

Timing the blood draw matters. Because T3 peaks within 2 to 4 hours of dosing, patients should take their NDT dose after the blood draw, not before, to avoid artificially elevated free T3 readings [4].